NASDAQ:GNMX - Aevi Genomic Medicine Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aevi Genomic Medicine Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.17 0.00 (0.00 %) (As of 02/27/2020 02:54 AM ET) Add Compare Today's Range$0.17Now: $0.17▼$0.1750-Day Range$0.17MA: $0.18▼$0.2252-Week Range$0.11Now: $0.17▼$0.35VolumeN/AAverage Volume3.16 million shsMarket Capitalization$12.89 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNMX Previous SymbolNASDAQ:MDGN CUSIPN/A CIK1138776 Webhttp://www.aevigenomics.com/ Phone610-254-4201Debt Debt-to-Equity RatioN/A Current Ratio0.65 Quick Ratio0.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book1.38Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-30,770,000.00 Net MarginsN/A Return on Equity-898.31% Return on Assets-286.73%Miscellaneous Employees14 Outstanding Shares77,714,000Market Cap$12.89 million Next Earnings Date4/3/2020 (Estimated) OptionableOptionable Receive GNMX News and Ratings via Email Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GNMX Rates by TradingView Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions What is Aevi Genomic Medicine's stock symbol? Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX." How were Aevi Genomic Medicine's earnings last quarter? Aevi Genomic Medicine Inc (NASDAQ:GNMX) posted its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.03. View Aevi Genomic Medicine's Earnings History. When is Aevi Genomic Medicine's next earnings date? Aevi Genomic Medicine is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aevi Genomic Medicine. Has Aevi Genomic Medicine been receiving favorable news coverage? Press coverage about GNMX stock has trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aevi Genomic Medicine earned a coverage optimism score of -4.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Aevi Genomic Medicine. Are investors shorting Aevi Genomic Medicine? Aevi Genomic Medicine saw a increase in short interest in January. As of January 31st, there was short interest totalling 338,700 shares, an increase of 28.7% from the January 15th total of 263,200 shares. Based on an average trading volume of 1,630,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.6% of the company's shares are short sold. View Aevi Genomic Medicine's Current Options Chain. Who are some of Aevi Genomic Medicine's key competitors? Some companies that are related to Aevi Genomic Medicine include INmune Bio (INMB), Allena Pharmaceuticals (ALNA), Idera Pharmaceuticals (IDRA), Neon Therapeutics (NTGN), Curis (CRIS), Polarityte (PTE), Organovo (ONVO), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), aTyr Pharma (LIFE), Vical (VICL), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP) and TRACON Pharmaceuticals (TCON). What other stocks do shareholders of Aevi Genomic Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include SCYNEXIS (SCYX), Ibio (IBIO), Biocept (BIOC), Immunomedics (IMMU), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Sierra Oncology (SRRA), Actinium Pharmaceuticals (ATNM), Protalix Biotherapeutics (PLX) and Co-Diagnostics (CODX). Who are Aevi Genomic Medicine's key executives? Aevi Genomic Medicine's management team includes the folowing people: Mr. Michael F. Cola, CEO, Pres & Director (Age 59)Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)Dr. Garry A. Neil, Chief Scientific Officer (Age 65) Who are Aevi Genomic Medicine's major shareholders? Aevi Genomic Medicine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.37%) and UBS Group AG (0.26%). Company insiders that own Aevi Genomic Medicine stock include Michael F Cola and Sol J Barer. View Institutional Ownership Trends for Aevi Genomic Medicine. Which institutional investors are buying Aevi Genomic Medicine stock? GNMX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and UBS Group AG. Company insiders that have bought Aevi Genomic Medicine stock in the last two years include Michael F Cola and Sol J Barer. View Insider Buying and Selling for Aevi Genomic Medicine. How do I buy shares of Aevi Genomic Medicine? Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aevi Genomic Medicine's stock price today? One share of GNMX stock can currently be purchased for approximately $0.17. How big of a company is Aevi Genomic Medicine? Aevi Genomic Medicine has a market capitalization of $12.89 million. The biotechnology company earns $-30,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Aevi Genomic Medicine employs 14 workers across the globe.View Additional Information About Aevi Genomic Medicine. What is Aevi Genomic Medicine's official website? The official website for Aevi Genomic Medicine is http://www.aevigenomics.com/. How can I contact Aevi Genomic Medicine? Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected] MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 194 (Vote Outperform)Underperform Votes: 228 (Vote Underperform)Total Votes: 422MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/27/2020 by MarketBeat.com StaffFeatured Article: What is a Tariff?
